SAN DIEGO, Feb. 15, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the completion of an underwritten public offering of 7,820,000 shares of its common stock, including 1,020,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriter. All of the shares were offered by Halozyme at a price to the public of $10.61 per share. The proceeds to Halozyme from this offering were approximately $81.8 million, after deducting the underwriting discounts and commissions but before expenses. The Company anticipates using the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes. Barclays Capital Inc. acted as the sole book-running manager for the offering.
The shares described above were offered by Halozyme, pursuant to a shelf registration statement on Form S-3ASR filed with the Securities and Exchange Commission (the "SEC"), and automatically declared effective on February 9, 2012. A final prospectus supplement relating to the offering was also filed with the SEC.
Copies of the final prospectus supplement and accompanying prospectus may be obtained free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, you may obtain a final prospectus supplement from the offices of Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; Barclaysprospectus@broadridge.com (phone: 888-603-5847).
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state in which such offer, solicitation or sale is not permitted.
About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the public offering) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission. Halozyme undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Halozyme's expectations.
Media/Investor Contact: Anne Erickson Executive Director Halozyme Therapeutics 858-704-8264 email@example.com
SOURCE Halozyme Therapeutics, Inc.